Tower Research Capital (TRC)’s Aspire Biopharma ASBP Stock Holding History

Tower Research Capital (TRC)’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.51K	Buy	283 +211	+293%	+$2.15K	﹤0.01%	4802
2026 Q1	$2.24K	Buy	72 +64	+800%	+$3.41K	﹤0.01%	4512
2025 Q4	$1.27K	Sell	8 -18	-69%	-$4.5K	﹤0.01%	4727
2025 Q3	$6.41K	Buy	+26	New	+$13K	﹤0.01%	4161
2023 Q4	–	Hold	0	–	-$87	–	6220
2023 Q3	–	Hold	0	–	–	–	5744
2023 Q2	–	Sell	-1	Closed	-$16K	–	6415
2023 Q1	$16K	Buy	+1	New	+$12.5K	﹤0.01%	3744
2022 Q4	–	Hold	0	–	–	–	5258
2022 Q3	–	Hold	0	–	–	–	5637
2022 Q2	–	Hold	0	–	–	–	5273

Other funds holding ASBP

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

VWM

Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return

Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Tower Research Capital (TRC)'s ASBP Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Aspire Biopharma (ASBP) stake by 293% in Q2 2026, buying an estimated $2.15K and bringing the position to 283 shares worth $1.51K. The position accounts for ﹤0.01% of the portfolio, ranked #4802.

Tower Research Capital (TRC) first reported a position in ASBP in Q1 2023 and has held it in 5 quarters since. The position peaked at $16K in Q1 2023. 13 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

Tower Research Capital (TRC) held 283 shares of Aspire Biopharma worth $1.51K as of Q2 2026.
Tower Research Capital (TRC) bought 211 Aspire Biopharma shares in Q2 2026, an estimated $2.15K.
Aspire Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4802 holding.
Tower Research Capital (TRC) first reported a position in Aspire Biopharma in Q1 2023 and has held it in 5 quarters since.
Tower Research Capital (TRC)'s Aspire Biopharma position peaked at $16K in Q1 2023.
13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.